Caption Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-424,500
Closed -$8.92M 2026
2025
Q4
$8.92M Sell
424,500
-194,300
-31% -$3.39M 0.06% 364
2025
Q3
$9.52M Buy
618,800
+129,900
+27% +$1.7M 0.07% 294
2025
Q2
$4.58M Buy
488,900
+238,900
+96% +$2.63M 0.05% 431
2025
Q1
$3.07M Buy
250,000
+126,700
+103% +$1.79M 0.03% 542
2024
Q4
$1.63M Sell
123,300
-2,900
-2% -$49.6K 0.02% 774
2024
Q3
$2.43M Buy
+126,200
New +$2.61M 0.04% 505
2024
Q1
Sell
-39,900
Closed -$862K 1638
2023
Q4
$862K Sell
39,900
-1,255,400
-97% -$19.3M 0.01% 838
2023
Q3
$18.8M Buy
1,295,300
+1,265,300
+4,218% +$23.9M 0.29% 73
2023
Q2
$628K Sell
30,000
-30,000
-50% -$625K 0.01% 770
2023
Q1
$1.27M Buy
+60,000
New +$1.49M 0.02% 572
2021
Q1
Sell
-15,700
Closed -$349K 1364
2020
Q4
$349K Buy
+15,700
New +$326K 0.01% 785
2020
Q3
Sell
-224,700
Closed -$3.33M 1236
2020
Q2
$3.33M Sell
224,700
-1,500
-0.7% -$22.8K 0.11% 250
2020
Q1
$2.48M Buy
226,200
+34,600
+18% +$325K 0.14% 199
2019
Q4
$1.68M Buy
191,600
+141,600
+283% +$1.04M 0.06% 389
2019
Q3
$374K Buy
+50,000
New +$455K 0.02% 522

Other funds holding SNDX

Caption Management's SNDX Position: Q3 2025 in Review

Caption Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 504,471 shares — an estimated $6.6M sold.

Caption Management first reported a position in SNDX in Q3 2018 and held it in 15 quarters. The position peaked at $4.72M in Q2 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Caption Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 504,471 Syndax Pharmaceuticals shares in Q3 2025, an estimated $6.6M.
  • Caption Management first reported a position in Syndax Pharmaceuticals in Q3 2018 and held it in 15 quarters.
  • Caption Management's Syndax Pharmaceuticals position peaked at $4.72M in Q2 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.